The Benzene Ring Is Part Of A Substituent Which Contains Sulfur Patents (Class 564/49)
  • Publication number: 20150056164
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 26, 2015
    Applicant: AbbVie Inc.
    Inventors: David A. Betebenner, John K. Pratt, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Kenton L. Longenecker, Clarence J. Maring, John T. Randolph, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Dachun Liu
  • Patent number: 8940681
    Abstract: The present invention improves dye transfer inhibition in the washing of textiles by the use of SO3M substituted urea derivatives of aromatic amines.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: January 27, 2015
    Assignee: Henkel AG & Co. KGaA
    Inventors: Mareile Job, Birgit Gluesen, John Taylor, Anthony Lawrence
  • Publication number: 20150005166
    Abstract: The present invention relates to solid forms of herbicide safeners, to processes for their preparation, compositions comprising the solid forms and methods of their use as safeners
    Type: Application
    Filed: February 8, 2013
    Publication date: January 1, 2015
    Applicant: SYNGENTA LIMITED
    Inventors: Ian Kevin Jones, Neil George, John Hone
  • Patent number: 8839960
    Abstract: The present disclosure relates to polymeric matrices composed of protected amine compound residues and membranes composed from such polymeric matrices. In particular, the present disclosure relates to a polymeric matrix comprising amine compound residues, acyl compound residues and protected amine compound residues.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: September 23, 2014
    Assignee: General Electric Company
    Inventor: Qingshan Jason Niu
  • Publication number: 20140171438
    Abstract: The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.
    Type: Application
    Filed: December 9, 2013
    Publication date: June 19, 2014
    Applicant: CELLCEUTIX CORPORATION
    Inventors: Wenxi Pan, Haizhong Tang
  • Publication number: 20130338231
    Abstract: The invention provides compound of the general formula: in which each X independently represents a polymer chain; n represents an integer greater than 1; Q represents a linker; Y represents an amide group; and Z represents either —CH.(CH2L)2 or —C(CH2L)(?CH2), in which each L independently represents a leaving group. The compounds are useful reagents for the conjugation of polymers to proteins, the resulting conjugates being novel and also forming part of the invention.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 19, 2013
    Inventors: Antony GODWIN, Stephen Brocchini
  • Patent number: 8541577
    Abstract: The present invention relates to novel aryl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: September 24, 2013
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 8507560
    Abstract: The present invention relates to a method of treating a disorder associated with modulation of the FPRL-1 receptor which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a 3,4-dihydroisoquinolin-2(1H)-yl-3-phenylurea derivative.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: August 13, 2013
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, John E. Donello, Michael E. Garst, Veena Viswanath
  • Publication number: 20130190396
    Abstract: Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO2NH2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.
    Type: Application
    Filed: January 9, 2013
    Publication date: July 25, 2013
    Applicant: METASIGNAL THERAPEUTICS INC.
    Inventor: METASIGNAL THERAPEUTICS INC.
  • Publication number: 20130053392
    Abstract: A carbonic anhydrase IX (CA IX) inhibitor which comprises a compound of general formula: R—NH—CX—NH—(CH2)n—Ar-Q-SO2—NH2 or a pharmaceutically-acceptable salt, derivative or prodrug thereof; wherein n=0, 1 or 2; Q is O or NH; X is O or S; and R comprises an organic substituent group.
    Type: Application
    Filed: February 14, 2011
    Publication date: February 28, 2013
    Inventors: Peter Ebbesen, Claudlu T. Supuran, Andrea Scozzafava, Erik Olai Pettersen, Kaye Williams, Ludwig Dubois, Philippe Lambin
  • Patent number: 8343963
    Abstract: The present invention relates to novel sulfamoyl-phenyl-ureido compounds having the formula (I) or a physiologically acceptable salt or derivative thereof which are suitable for the therapy of infections caused by protozoa and in particular uncomplicated or severe malaria caused by plasmodia.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: January 1, 2013
    Assignee: 4SC AG
    Inventor: Stefano Pegoraro
  • Publication number: 20120329786
    Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 27, 2012
    Applicant: Myrexis, Inc.
    Inventors: J. Adam Willardsen, Jeffrey W. Lockman, Brett R. Murphy, Weston R. Judd, In Chul Kim, Se-Ho Kim, Daniel Feodore Zigar, Kraig M. Yager, Tracey C. Fleischer, Ryan T. Terry-Lorenzo, J. Jay Boniface, Daniel P. Parker, Ian A. McAlexander, Matthew Gregory Bursavich, David M. Dastrup
  • Publication number: 20120082646
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Application
    Filed: March 25, 2010
    Publication date: April 5, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: David A. Betebenner, John K. Pratt, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Kenton L. Longenecker, Clarence J. Maring, John T. Randolph, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Dachun Liu
  • Publication number: 20110275635
    Abstract: Small molecule inhibitors of bacterial nicotinamide adenine dinucleotide synthetase (NADs), bacterial nicotinic acid mononucleotide adenylyltransferase (NaMNAT), and human nicotinamide mononucleotide adenylyltransferase (NMNAT) are provided, as well as methods of making and using the inhibitors.
    Type: Application
    Filed: January 8, 2010
    Publication date: November 10, 2011
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Wayne J. Brouillette, Christie G. Brouillette, Whitney B. Moro
  • Publication number: 20110071142
    Abstract: The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor. The present invention also relates to various compounds described herein (e.g.
    Type: Application
    Filed: March 19, 2010
    Publication date: March 24, 2011
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Peter Oettgen, Alan C. Rigby, Towia Libermann
  • Publication number: 20100298344
    Abstract: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis.
    Type: Application
    Filed: March 10, 2010
    Publication date: November 25, 2010
    Inventors: Shaker Mousa, Dahui Liu
  • Publication number: 20100197640
    Abstract: The present invention relates to novel sulfamoyl-phenyl-ureido compounds having the formula (I) or a physiologically acceptable salt or derivative thereof which are suitable for the therapy of infections caused by protozoa and in particular uncomplicated or severe malaria caused by plasmodia.
    Type: Application
    Filed: January 29, 2010
    Publication date: August 5, 2010
    Applicant: 4SC AG
    Inventor: Stefano PEGORARO
  • Patent number: 7741351
    Abstract: This case discloses compounds of formula (I) wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano or amino; each R4, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; p is 0, 1 or 2; each R5, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; q is 0, 1 or 2; R6 is —NR6aSO2R6b, —NR6aC(?O)R6b, —NR6a(C?O)N(R6c)2, —(C?O)R6d, —CH2NR6aSO2R6b, —CH2NR6aC(?O)R6b, CH2NR6a(C?O)N(R6c)2 or —CH2(C?O)R6d; where R6a and each R6c, which may be the same or different, is hydrogen or C1-6alkyl; R6b and R6d are C1-6alkyl or haloC1-6alkyl; or R6a and R6b, or R6a and R6c, together with the interconnecting atoms, may form a 5- or 6-membered ring; n is 1 or 2; and R7 and R8, which may be the same or different, are
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: June 22, 2010
    Assignee: Glaxo Group Limited
    Inventors: Kevin Michael Thewlis, Simon Edward Ward
  • Publication number: 20100120754
    Abstract: The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor.
    Type: Application
    Filed: May 6, 2009
    Publication date: May 13, 2010
    Inventors: Peter Oettgen, Alan Rigby, Towia Libermann
  • Publication number: 20100048573
    Abstract: The present invention relates to compounds and methods for the treatment of bacterial infections. Because their mechanism of action does not involve killing of bacteria or inhibiting their growth, the potential for these compounds to induce drug resistance in bacteria is minimized. Through inhibiting bacterial virulence, the present invention provides a novel means of treating bacterial infections.
    Type: Application
    Filed: October 20, 2008
    Publication date: February 25, 2010
    Inventors: Vanessa Sperandio, John R. Falck, Donald R. Stewart
  • Patent number: 7579378
    Abstract: The invention relates to sulfonamido derivatives of formula (I) wherein R1-R7 are as defined in the description. Compounds (I) antagonize the vanilloid receptor and can be used for the preparation of medicaments for the treatment of inflammatory states.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: August 25, 2009
    Assignee: Pharmeste S.R.L.
    Inventors: Pier Giovanni Baraldi, Pier Andrea Borea, Pierangelo Geppetti
  • Publication number: 20090137594
    Abstract: The present invention relates to pentafluorosulphanyl-substituted compounds, methods for their production, medicaments containing such compounds and the use of such compounds for producing medicaments.
    Type: Application
    Filed: May 17, 2006
    Publication date: May 28, 2009
    Applicant: Gruenenthal GmgH
    Inventors: Robert Frank, Bernd Sundermann, Hans Schick
  • Patent number: 7501442
    Abstract: This invention provides compounds of formula I: wherein a, b, c, m, p, r, R1, R2, R3, R4, R5, R6, W and X1 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: March 10, 2009
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, Yu-Hua Ji, Craig Husfeld
  • Publication number: 20080207622
    Abstract: Disclosed are sulfone compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetes-related diseases.
    Type: Application
    Filed: September 28, 2007
    Publication date: August 28, 2008
    Inventor: Richard D. Gless
  • Publication number: 20080207621
    Abstract: Disclosed are sulfonamide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetes-related diseases.
    Type: Application
    Filed: September 28, 2007
    Publication date: August 28, 2008
    Inventor: Richard D. Gless
  • Patent number: 7399788
    Abstract: Disclosed is a series of N-deacetylthiocolchicine derivatives of formula (I) in which: the linker is a bivalent straight or branched C1-C8 alkyl residue, C3-C8 cycloalkyl, a phenylene or heterocyclic C4-C6 ring; the G1 and G2 junctions, which can be the same or different, are —CO—, —COHN—, —CR2— groups in which R2 is hydrogen or a straight C1-C4 alkyl residue, or the G1-linker-G2 group is the —CO— group. The compounds of formula (I) have antiproliferative, antinflammatory, antiarthritic and antiviral activity.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: July 15, 2008
    Assignee: Indena S.p.A.
    Inventors: Ezio Bombardelli, Gabriele Fontana
  • Patent number: 7071231
    Abstract: Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: July 4, 2006
    Assignee: Telik, Inc.
    Inventors: Wayne R. Spevak, Songyuan Shi, Prasad V. V. S. V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum
  • Patent number: 7064229
    Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: June 20, 2006
    Assignee: Bayer Healthcare AG
    Inventors: Thomas Rolle, Thomas Lehmann, Markus Albers, Gerhard Muller, Gerhard Hessler, Rudiger Fischer, Masaomi Tajimi, Karl Ziegelbauer, Kevin Bacon, Haruki Hasegawa, Hiromi Okigami
  • Patent number: 7060718
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: June 13, 2006
    Assignee: Amgen Inc.
    Inventor: Jonathan B. Houze
  • Patent number: 7034045
    Abstract: The present invention provides certain monofluoroalkyl derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: April 25, 2006
    Assignee: Eli Lilly and Company
    Inventors: David Michael Bender, Buddy Eugene Cantrell, Andrew Hendley Fray, Winton Dennis Jones, William David Miller, David Mitchell, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6949567
    Abstract: The invention relates to new diphenylurea having the formula (I) or a salt thereof, where Y is C?O, C?S, C?NH, (C?O)2 or SO2; and to processes for the preparation of these compounds and to their use in the treatment of protozoal diseases and to diseases where the inhibition of intracellular protein-degradation pathways is of benefit.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: September 27, 2005
    Assignee: 4SC AG
    Inventors: Andrea Aschenbrenner, Katharina Aulinger Fuchs, Matthias Dormeyer, Gabriel Garcia, Bernd Kramer, Jürgen Kraus, Rolf Krauss, Johan Leban, Stefano Pegoraro, Wael Saeb, Kristina Wolf
  • Patent number: 6911457
    Abstract: The present invention relates to novel imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: June 28, 2005
    Assignee: Carbomer, Inc.
    Inventor: Manssur Yalpani
  • Patent number: 6838472
    Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: January 4, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Michael Klaus, Jean-Marc Lapierre
  • Patent number: 6815556
    Abstract: A compound according to formula one that is useful as a fungicide is provided. Additionally, processes to make and use same are provided.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: November 9, 2004
    Assignee: Dow AgroSciences LLC
    Inventors: Carla Jean Rasmussen Klittich, Jeannie Rachel Cetusic, Marilene Tenguan Iamauti, Irene Mae Morrison, Michael Thomas Sullenberger, William Chi-Leung Lo, Ann Marie Buysse, Brent Jeffrey Rieder, John Todd Mathieson, Monica Britt Olson, Michael John Ricks
  • Publication number: 20040167131
    Abstract: This invention discloses amino acid derivatives which display inhibitory effects on the serine protease factor Xa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, methods for the preparation of the compounds, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.
    Type: Application
    Filed: September 11, 2003
    Publication date: August 26, 2004
    Applicant: Pfizer Inc.
    Inventors: Gary Louis Bolton, Kevin James Filipski, Jeffrey Thomas Kohrt, Frances La, Daniele Marie Leonard
  • Patent number: 6767922
    Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: July 27, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine Louisa Widdowson, Qi Jin
  • Patent number: 6765009
    Abstract: Disclosed are novel 1,4-disubstituted benzo-fused compounds wherein G, X, L, Q, n and Y are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: July 20, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Pier Francesco, Daniel R. Goldberg, Abdelhakim Hammach, Neil Moss, Kristen Mueller, John Robinson Regan
  • Publication number: 20040102636
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: February 1, 2002
    Publication date: May 27, 2004
    Applicant: BAYER CORPORATION
    Inventors: Scott Miller, Martin Osterhout, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, David E. Gunn, Holia Hatoum-Mokdad, Marell Rodriguez, Robert Sibley, Ming Wang, Tiffany Turner, Catherine Brennan
  • Publication number: 20040092412
    Abstract: Compounds, in particular those based on polyisobutyleneamines, are suitable as emulsifiers for water-in-oil emulsions and are used in particular as additives for fuels and lubricants.
    Type: Application
    Filed: September 2, 2003
    Publication date: May 13, 2004
    Inventors: Stephan Hueffer, Cordula Mock-Knoblauch, Gregor Schrmann, Arno Lange
  • Patent number: 6664259
    Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: December 16, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine Louisa Widdowson, Qi Jin
  • Publication number: 20030207939
    Abstract: The present invention relates to a urea derivative of the formula (1) 1
    Type: Application
    Filed: February 5, 2003
    Publication date: November 6, 2003
    Inventors: Seigo Ishibuchi, Hiroshi Sumichika, Katsuhiko Itoh, Yoichi Naka
  • Publication number: 20030125383
    Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
    Type: Application
    Filed: September 17, 2002
    Publication date: July 3, 2003
    Applicant: Roche Bioscience, a division of Syntex (U.S.A.) LLC
    Inventors: Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20030109527
    Abstract: The invention relates to novel hydroxy diphenylurea sulfonamides, compositions and intermediates thereof. The hydroxy diphenylurea sulfonamides are useful in the treatment of disease states mediated by the chemokine, Interleukin-8.
    Type: Application
    Filed: November 18, 2002
    Publication date: June 12, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: Qi Jin, Brent W. McCleland, Michael R. Palovich, Katherine L. Widdowson
  • Publication number: 20030100608
    Abstract: Disclosed are compounds of the formula (I) shown below which are active as anti-inflammatory agents. Also disclosed are methods of using and making such compounds.
    Type: Application
    Filed: May 24, 2002
    Publication date: May 29, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Pier Francesco Cirillo, Eugene R. Hickey
  • Publication number: 20030078250
    Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Application
    Filed: September 6, 2002
    Publication date: April 24, 2003
    Inventors: Katherine Louisa Widdowson, Qi Jin
  • Publication number: 20030055248
    Abstract: This invention relates to novel compounds and compositions thereof useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Application
    Filed: October 7, 2002
    Publication date: March 20, 2003
    Inventors: Michael R. Palovich, Katherine L. Widdowson, Hong Nie
  • Patent number: 6525091
    Abstract: Substituted diarylureas, pharmaceutical compositions containing them, and their use for stimulating Fas-mediated apoptosis. The compounds, as single stereoisomers or mixtures of stereoisomers, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful in methods of treating autoimmune diseases, infectious diseases, and malignancies.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: February 25, 2003
    Assignee: Telik, Inc.
    Inventors: Louise Robinson, Hugo O. Villar
  • Patent number: 6515023
    Abstract: A thrombin receptor antagonist having the formula useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: February 4, 2003
    Assignee: Merck & Co., Inc.
    Inventors: James C. Barrow, Philippe G. Nantermet, Harold G. Selnick, John H. Hutchinson, Michael J. Breslin, Kristen L. Glass, Thomas M. Connolly, Andrew Stern
  • Patent number: 6515176
    Abstract: Disclosed is a 6-acylamino-5-substituted-benzoxazol-2-one compound having the structural formula I: wherein Y is halogen or a substituent group linked to the rest of the compound by a hetero atom, and R′ is a group containing at least 8 carbon atoms. Also disclosed is a method for forming a cyan dye-forming coupler from the above compound. The method and intermediate provide a simplified manufacturing process.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: February 4, 2003
    Assignee: Eastman Kodak Company
    Inventor: Chang-Kyu Kim
  • Publication number: 20030013835
    Abstract: A polyurea composition free from polyol linkages. A composition and process for producing a two component spray 100% polyurea elastomeric system wherein an A and a B component are mixed, wherein said A component is a prepolymer produced by an aromatic isocyanate and amine terminated materials and wherein said B component is 100% amine terminated reactive ingredients. The instant invention can be used as a spray system for lining and coating surfaces.
    Type: Application
    Filed: April 25, 2001
    Publication date: January 16, 2003
    Inventors: Anastasios Zahariadis, Gerald Thermos